

Antibacterial Secondary Metabolites from Basidiomycetes

Subjects: Biochemistry & Molecular Biology

Contributor: Getha Krishnasamy

Fungi are a rich source of secondary metabolites with several pharmacological activities such as antifungal, antioxidant, antibacterial and anticancer to name a few. Due to the large number of diverse structured chemical compounds they produce, fungi from the phyla Ascomycota, Basidiomycota and Mucoromycota have been intensively studied for isolation of bioactive compounds. Basidiomycetes-derived secondary metabolites are known as a promising source of antibacterial compounds with activity against Gram-positive bacteria. The continued emergence of antimicrobial resistance (AMR) poses a major challenge to patient health as it leads to higher morbidity and mortality, higher hospital-stay duration and substantial economic burden in global healthcare sector. One of the key culprits for AMR crisis is *Staphylococcus aureus* causing community-acquired infections as the pathogen develops resistance towards multiple antibiotics. The recent emergence of community strains of *S. aureus* harbouring methicillin-resistant (MRSA), vancomycin-intermediate (VISA) and vancomycin-resistant (VRSA) genes associated with increased virulence is challenging. Despite the few significant developments in antibiotic research, successful MRSA therapeutic options are still needed to reduce the use of scanty and expensive second-line treatments. This paper provides an overview of findings from various studies on antibacterial secondary metabolites from basidiomycetes, with a special focus on antistaphylococcal activity.

Keywords: Basidiomycota ; bioactive natural products ; antibacterial ; antimicrobial resistance

1. Introduction

Antimicrobial resistance (AMR) crisis is associated with more than 2 million hard-to-treat infectious diseases. The Center for Disease Control and Prevention (CDC) reported that increasing mortality rate at an average of 23,000 deaths per year was recorded in developing countries ^[1]. Major pathogen that contributes to the AMR incidence is *Staphylococcus aureus* with the emergence of multidrug-resistant strains such as methicillin-resistant (MRSA), vancomycin-intermediate (VISA) and vancomycin-resistant (VRSA) *S. aureus* ^{[2][3][4]}. The rising incidence of these resistant pathogens leads to inadequate antimicrobial therapeutic effects that are related to poor healthcare outcome in patients. Community-acquired methicillin-resistant *S. aureus* (CA-MRSA) strains also account for an increasing proportion of hospital-acquired MRSA (HA-MRSA) infections ^{[3][5]}. These pathogenic strains of *Staphylococci* with their intrinsic virulence factor can cause a diverse array of life-threatening infections ^[4]. The high antibiotic selective pressure in crowded populations, like in Asia, creates an environment that allows rapid development and successful spread of multidrug-resistant pathogens such as HA-MRSA and CA-MRSA ^{[3][6]}. The last resort treatment for MRSA infections is vancomycin ^[2]. However, current loss in sensitivity toward vancomycin limits the conventional therapeutic choice for *Staphylococcal* infections ^{[2][7]}.

Fungal secondary metabolites have been reported as a potential source of bioactive compounds with antibacterial activity. The accidental discovery of penicillin from fungi in 1929 by Fleming drew attention of scientific community to the possible role of fungi as antibiotics and this has contributed to the isolation and development of other antibiotics ^[8]. Fungi are rich sources of secondary metabolites with diverse bioactivities, many that have been developed into important pharmaceutical products. With more than 15,000 secondary metabolites discovered to date, fungi stand out as an important group of microbes in bioactive natural products research ^[9]. Advances in analytical chemistry, computational tools, and drug discovery research have enabled the development of some fungal-derived antimicrobial compounds with potential therapeutic effects to be used individually or in adjunctive therapies to control difficult-to-treat pathogens ^[10]. Secondary metabolites from saprotrophic and easily cultivable fungi of the phyla Ascomycota, Mucoromycota and Basidiomycota have been studied intensively ^[11].

Previous studies have shown that secondary metabolites from basidiomycetes have a wide range of pharmacological activities including antimicrobials ^[12]. Basidiomycetes, from the phylum Basidiomycota, are a group of higher fungi with distinctive fruiting bodies and reproductive structures with edible and non-edible properties. Mushroom-forming fungi,

mostly from the basidiomycete group, have been used as remedies for various diseases owing to their ability to produce compounds with high structural diversity, including terpenes, anthraquinone, derivatives of benzoic acid, quinolines, cyclic peptides, steroids, sesquiterpenes, oxalic acid, epipolythiopiperazine-2,5 diones and polysaccharides [13][14]. Traditionally, bioactive components have been extracted from fruiting bodies or mycelial extracts of mushrooms [15]. They are known to produce secondary metabolites with a range of pharmacological activities including antimicrobial, antioxidant, anti-angiogenesis, anticancer, immunomodulatory and anti-inflammatory [16].

In many studies, however, antimicrobial activities of different extracts of mushroom were reported without identifying the active compound/s responsible for the observed high activity against Gram-positive bacteria [13][17][18]. Despite the challenges faced in explorative studies to access the bioactive metabolites originating from fruiting bodies of mushrooms as they occur temporarily in the environment, their importance has been significant in recent decades [13]. With regards to this, more studies have been focusing on metabolites produced from submerged fermentation of mycelial culture of mushrooms where frequently these metabolites differ from those of fruiting bodies [19]. This work is a brief review on antistaphylococcal activities of Basidiomycetes that have been reported.

2. Antimicrobial Resistance (AMR)

Antimicrobial resistance is described as lowered efficiency or loss of antibiotics' effectiveness against pathogens and this is a major problem in the medical sector globally. Antimicrobial resistance is correlated with high medical costs because of a longer period of disease, additional testing and needless usage of second-line treatments [1][9]. As mentioned by the Organization for Economic Co-operation and Development (OECD), the key risk factor for development of resistance is excessive usage or intake of antibiotics [6][20][21]. The high emergence of AMR has led to a shift change in therapeutic practices towards use of newer wide-spectrum drugs and increased usage (42%) of last resort classes of antibiotics such as vancomycin [6]. Many reports have indicated that the resistance epidemiology is global and spreads through nations and across borders [20].

In vitro antibacterial activity of antibiotics is typically determined by biological assays. The most popular methods include agar well diffusion, disc diffusion, minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and time kill assays [22]. Clinical breakpoints used as interpretive criteria to consider susceptibility of a bacterial isolate to an antimicrobial agent are provided by the Clinical and Laboratory Standards Institute (CLSI) [23][24], the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and/or the US Food and Drug Administration (FDA).

In agar well diffusion assay, a hole was punched into agar inoculated with the test organism and filled with the antibiotic solution. Alternatively, a filter paper disc containing antibiotic was placed on inoculated agar. In both methods, zone of inhibition produced by the diffusion of antibiotic compound into the agar was measured. Due to the agar being an aqueous preparation, non-polar compounds do not diffuse as well as polar compounds, thus producing smaller diameter of inhibition zones despite their higher activity. This could be a limitation in the agar diffusion method [25][26]. The MIC is defined as the lowest concentration of a drug that inhibits the growth of bacteria after incubation. The MBC of a drug is determined upon reading of MIC by streaking the broth dilutions onto general or selective agar with 24–48 h of incubation. Absence of growth of the viable organisms on agar indicated the lowest broth dilution of drug, which caused a 99.9% suppression of the bacterial growth. The most appropriate *in vitro* approach to study bactericidal activity of a vast variety of antimicrobial agents is the time-kill assay [22]. The outcome of this assay indicates if an antimicrobial effect is dependent on exposure time or concentration of the drug. The assay is often used as initial descriptive analysis in pharmacodynamic analysis of a drug [22][27].

Preventing the development of resistant bacterial strains is important to ensure the effectiveness of current drugs in managing dangerous and life-threatening infections as an attempt to reduce the severity of AMR crisis [28][29]. Thus, there is an urgent need to carry out continuous research and development of new antibacterial drugs to counter the loss in efficacy of current antibiotics [28][30][31].

3. Multidrug Resistant *Staphylococcus aureus* and Antibacterial Drug Discovery from Basidiomycetes

Staphylococcus aureus infections produce wide spectrum of pyogenic lesions involving several organs, and it can cause hospital outbreaks and community acquired infections. Selective pressure on the bacteria due to high consumption of wide-spectrum antibiotics could stimulate the emergence of antibacterial resistant strains. Burden of infections in low-income countries is high since the solution to overcome this crisis is by replacing ineffective first line antibiotics to more costly second line or third line antibiotics [6]. Thus, the development of new antibiotics, combination drugs, bioprospecting

for potential antibacterial natural compounds and improved drug delivery systems are some of the current strategies to control the antimicrobial resistance threat [6][32].

Emergence of HA-MRSA strains are associated with profligate use of antibiotics in healthcare settings [33]. The MRSA strains have demonstrated resistance to a range of antibiotics belonging to isoxazoyl penicillin group (methicillin, oxacillin, flucloxacillin), cephalosporins and carbapenems [34][35][36]. The first MRSA variant strain was isolated in United Kingdom in 1961 after methicillin was introduced in 1959 [37][38][39][40]. Thereafter, the changing epidemiology of variants of the strains found in many other countries like Europe, Australia, Japan and United States eventually makes MRSA as a major threat in nosocomial infections worldwide [20]. MRSA has more propensity to develop resistance to macrolides, quinolones and aminoglycosides, and this led to reduced therapeutic options [34][35][36][41][42]. In hospitals worldwide, a high prevalence of MRSA with rates above 50% has been documented [43][44]. A new variant strain of CA-MRSA was reported to be prevalent in Asian healthcare settings. This was documented by several studies which showed an occurrence rate of 2.5% in Thailand and 38.8% in Sri Lanka [45].

Emergence of antimicrobial resistance in *S. aureus* to glycopeptide group of antibiotics which is the last resort of staphylococcal treatment, became a global concern in managing staphylococcal infections [29]. Three classes of limited vancomycin susceptibility strains of *S. aureus* that have emerged in different locations around the world are VISA, heterogeneous VISA (hVISA) and VRSA [37][46]. Owing to the dynamic re-organisation of cell wall metabolism, VISA and hVISA strains have thickened cell walls with decreased glycopeptide cross-linking [44]. The first report of VISA and hVISA was detected in Japan in 1996 and 1997, respectively, while VRSA from a hospital in the United States was reported in 2002 [47]. The resistance phenotypic of VISA (Minimum Inhibitory Concentration: 8 µg/mL) has the ability of reverting back to the susceptibility phenotype towards vancomycin when the selective pressure is removed (MIC at 2 µg/mL) [48].

Prevalence of VRSA strains have been documented in South Nigeria (0–6%), Zaria, North Nigeria (57.7%), South India (1.4%), Australia, South Africa, Scotland, Hong Kong, Thailand and Korea (0–74%) [39][48][49][50]. No reports of vancomycin-resistant *S. aureus* (VRSA) have been documented in Malaysia [51]. The emergence of antibiotic resistance globally could lead to serious problems of limited therapeutic options available [52]. The emergence of VISA and VRSA strains causes more life-threatening infections in the healthcare sector [53][54]. Scanty and expensive drugs like teicoplanin, daptomycin and linezolid are also being used as next therapeutic options for MRSA infection due to the limited sensitivity of vancomycin [15][35][54][55][56].

Basidiomycetes derived secondary metabolites are known as a promising source of antibacterial compounds with activity against Gram-positive bacteria in natural product discovery. Crude extracts of natural products were reported to target on cell wall biosynthesis and cell membrane permeability as their mechanism of action to exhibit antibacterial activity [57]. Many species have been studied for their potential to produce bioactive secondary metabolites with antibacterial activity against MRSA and other drug resistant bacteria [58][59][60][61][62][61][63][64][65][66][67][68].

References

1. World Health Organization. WHO Report on Surveillance of Antibiotic Consumption: 2016–2018 Early Implementation. 2018. Available online: https://www.who.int/medicines/areas/rational_use/oms-amr-amc-report-2016-2018/en/ (accessed on 22 September 2020).
2. Magiorakos, A.P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. *Clin. Microbiol. Infect.* 2012, 18, 268–281.
3. Basak, S.; Singh, P.; Rajurkar, M. Multidrug resistant and extensively drug resistant bacteria: A study. *J. Pathog.* 2016, 2016, 1–5.
4. Health Research & Educational Trust. Multi-Drug Resistant Organism Infection Change Package: 2017 Update. Chicago. Available online: www.hret-hiin.org (accessed on 20 September 2020).
5. World Bank. Drug-Resistant Infections: A Threat to Our Economic Future: Washington, DC, 2017. Available online: <http://documents.worldbank.org/curated/en/323311493396993758/> (accessed on 22 September 2020).
6. Laxminarayan, R.; Matsoso, P.; Pant, S.; Brower, C.; Røttingen, J.A.; Klugman, K.; Davies, S. Access to effective antimicrobials: A worldwide challenge. *Lancet* 2016, 387, 168–175.
7. Dhanalakshmi, T.A.; Umaphathy, B.L.; Mohan, D.R. Prevalence of Methicillin, Vancomycin and Multidrug Resistance among *Staphylococcus aureus*. *J. Clin. Diagn. Res.* 2012, 6, 974–977.

8. Fleming, A. On the antibacterial action of cultures of a penicillium with, special reference to their use in the isolation of *B. influenzae*. *Br. J. Exp. Pathol.* 1929, 10, 226–236.
9. Bills, G.F.; Gloer, J.B. Biologically active secondary metabolites from the fungi. *Fungal Kingd.* 2017, 1087–1119.
10. Betts, J.W.; Wareham, D.W. In vitro activity of curcumin in combination with epigallocatechin gallate (EGCG) versus multidrug-resistant *Acinetobacter baumannii*. *BMC Microbiol.* 2014, 14, 172.
11. Stodulkova, E.; Cisarova, I.; Kolarik, M.; Chudickova, M.; Novak, P.; Man, P.; Flieger, M. Biologically active metabolites produced by the basidiomycete *Quambalaria cyanescens*. *PLoS ONE* 2015, 10.
12. Bala, N.; Aitken, E.A.; Fechner, N.; Cusack, A.; Steadman, K.J. Evaluation of antibacterial activity of Australian basidiomycetous macrofungi using a high-throughput 96-well plate assay. *Pharm. Biol.* 2011, 49, 492–500.
13. Alves, M.J.; Ferreira, I.C.F.R.; Martins, A.; Pintado, M. Antimicrobial activity of wild mushroom extracts against clinical isolates resistant to different antibiotics. *J. Appl. Microbiol.* 2012, 113, 466–475.
14. De Silva, D.D.; Rapior, S.; Sudarman, E.; Stadler, M.; Xu, J.; Aisyah Alias, S.; Hyde, K.D. Bioactive metabolites from macrofungi: Ethnopharmacology, biological activities and chemistry. *Fungal Divers.* 2013, 62, 1–40.
15. Kaur, H.; Sharma, S.; Khanna, P.K.; Kapoor, S. Evaluation of *Ganoderma lucidum* strains for the production of bioactive components and their potential use as antimicrobial agents. *J. Appl. Nat. Sci.* 2015, 7, 298–303.
16. Wasser, S.P. Medicinal mushroom science: History, current status, future trends, and unsolved problems. *Int. J. Med. Mushrooms* 2010, 12, 1–16.
17. Beni, Z.; Dekany, M.; Kovacs, B.; Csopor-Löffler, B.; Zomborszki, Z.P.; Kerekes, E.; Vanyolos, A. Bioactivity-guided isolation of antimicrobial and antioxidant metabolites from the mushroom *Tapinella atrotomentosa*. *Molecules* 2018, 23, 1082.
18. Ling, L.L.; Schneider, T.; Peoples, A.J.; Spoering, A.L.; Engels, I.; Conlon, B.P.; Mueller, A.; Schaberle, T.F.; Hughes, D.E.; Epstein, S.; et al. A new antibiotic kills pathogens without detectable resistance. *Nature* 2015, 517, 455–459.
19. Lindequist, U.; Niedermeyer, T.H.; Julich, W.D. The pharmacological potential of mushrooms. *Evid. Based Complement. Altern. Med.* 2005, 2.
20. Cecchini, M.; Langer, J.; Slawomirski, L. Antimicrobial Resistance in G7 Countries and Beyond: Economic Issues, Policies and Options for Action; Organization for Economic Co-operation and Development: Paris, France, 2015; pp. 1–75.
21. Mendelson, M.; Røttingen, J.A.; Gopinathan, U.; Hamer, D.H.; Wertheim, H.; Basnyat, B.; Balasegaram, M. Maximising access to achieve appropriate human antimicrobial use in low-income and middle-income countries. *Lancet* 2016, 387, 188–198.
22. Jorgensen, J.H.; Ferraro, M.J. Antimicrobial susceptibility testing: General principles and contemporary practices. *Clin. Infect. Dis.* 1998, 26, 973–980.
23. CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 27th ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2017; ISBN 1-56238-1-56238-805-3.
24. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters; Version 10; 2020; Available online: <http://www.eucast.org> (accessed on 5 December 2020).
25. Janes, D.; Kreft, S.; Jurc, M.; Seme, K.; Strukelj, B. Antibacterial activity in higher fungi (mushrooms) and endophytic fungi from Slovenia. *Pharm. Biol.* 2007, 45, 700–706.
26. Lund, R.G.; Del Pino, F.A.B.; Serpa, R.; Nascimento, J.S.; DA Silva, V.M.; Ribeiro, G.A.; Rosalen, P.L. Antimicrobial activity of ethanol extracts of *Agaricus brasiliensis* against mutants streptococci. *Pharm. Biol.* 2009, 47, 910–915.
27. Taufiq, M.M.J.; Darah, I. Anti-MRSA of the ethyl acetate crude extract from *Lasioidiplodia pseudotheobromae* IBRL OS-64, an endophytic fungus isolated from leaf of *Ocimum sanctum* Linn. *Int. J. Pharm. Pharm. Sci.* 2018, 10, 50–55.
28. Khameneh, B.; Diab, R.; Ghazvini, K.; Bazzaz, B.S.F. Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them. *Microb. Pathog.* 2016, 95, 32–42.
29. Liu, M.; Lu, J.; Muller, P.; Turnbull, L.; Burke, C.M.; Schlothauer, R.C.; Harry, E.J. Antibiotic-specific differences in the response of *Staphylococcus aureus* to treatment with antimicrobials combined with manuka honey. *Front. Microbiol.* 2015, 5, 779.
30. Al-Talib, H.; Al-Khateeb, A.; Hassan, H. Antimicrobial resistance of *Staphylococcus aureus* isolates in Malaysian Tertiary Hospital. *Int. Med. J.* 2015, 22, 1–3.
31. Hyde, K.D.; Xu, J.; Rapior, S.; Jeewon, R.; Lumyong, S.; Niego, A.G.T.; Abeywickrama, P.D.; Aluthmuhandiram, J.V.S.; Brahmananage, R.S.; Brooks, S.; et al. The amazing potential of fungi: 50 ways we can exploit fungi industrially. *Fungal Divers.* 2019, 97, 1–136.

32. Lazar, V.; Ditu, L.M.; Pircalabioru, G.G.; Gheorghe, I.; Curutiu, C.; Holban, A.M.; Picu, A.; Petcu, L.; Chifiriuc, M.C. Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. *Front. Immunol.* 2018, 9, 1830.
33. Shaffer, R.K. The challenge of antibiotic-resistant *Staphylococcus*: Lessons from hospital nurseries in the mid-20th century. *Yale J. Biol. Med.* 2013, 86, 261.
34. Adhikari, R.; Pant, N.D.; Neupane, S.; Neupane, M.; Bhattarai, R.; Bhatta, S.; Lekhak, B. Detection of methicillin resistant *Staphylococcus aureus* and determination of minimum inhibitory concentration of vancomycin for *Staphylococcus aureus* isolated from pus/wound swab samples of the patients attending a tertiary care hospital in Kathmandu, Nepal. *Can. J. Infect. Dis. Med. Microbiol.* 2017.
35. Arunkumar, V.; Prabagaravarathanan, R.; Bhaskar, M. Prevalence of Methicillin-resistant *Staphylococcus aureus* (MRSA) infections among patients admitted in critical care units in a tertiary care hospital. *Int. J. Res. Med. Sci.* 2017, 5, 2362–2366.
36. Onyeji, C.O.; Bui, K.Q.; Owens, R.C., Jr.; Nicolau, D.P.; Quintiliani, R.; Nightingale, C.H. Comparative efficacies of levofloxacin and ciprofloxacin against *Streptococcus pneumoniae* in a mouse model of experimental septicaemia. *Int. J. Antimicrob. Agents* 1999, 12, 107–114.
37. Appelbaum, P.C. Reduced glycopeptide susceptibility in methicillin-resistant *Staphylococcus aureus* (MRSA). *Int. J. Antimicrob. Agents* 2007, 30, 398–408.
38. Harkins, C.P.; Pichon, B.; Doumith, M.; Parkhill, J.; Westh, H.; Tomasz, A.; Holden, M.T. Methicillin-resistant *Staphylococcus aureus* emerged long before the introduction of methicillin into clinical practice. *Genome Biol.* 2017, 18, 130.
39. Loomba, P.S.; Taneja, J.; Mishra, B. Methicillin and vancomycin resistant *S. aureus* in hospitalized patients. *J. Glob. Infect. Dis.* 2010, 2, 275.
40. Okwu, M.U.; Olley, M.; Akpoka, A.O.; Izevbuwa, O.E. Methicillin-resistant *Staphylococcus aureus* (MRSA) and anti-MRSA activities of extracts of some medicinal plants: A brief review. *AIMS Microbiol.* 2019, 5, 117–137.
41. Morales, E.; Cots, F.; Sala, M.; Comas, M.; Belvis, F.; Riu, M.; Salvado, M.; Grau, S.; Horcajada, J. Hospital costs of nosocomial multi-drug resistant *Pseudomonas aeruginosa* acquisition. *BMC Health Serv. Res.* 2012, 12, 122.
42. Saaqi, M.; Ahmad, S.; Zaib, M.S. Burn wound infections and antibiotic susceptibility patterns at Pakistan Institute of Medical Sciences, Islamabad, Pakistan. *World J. Plastic Surg.* 2015, 4, 9.
43. Sit, P.S.; The, C.S.; Idris, N.; Sam, I.C.; Syed Omar, S.F.; Sulaiman, H.; Thong, K.L.; Kamarulzaman, A.; Ponnampalavan, S. Prevalence of methicillin-resistant *Staphylococcus aureus* (MRSA) infection and the molecular characteristics of MRSA bacteraemia over a two-year period in a tertiary teaching hospital in Malaysia. *BMC Infect. Dis.* 2017, 17, 1–14.
44. Stefani, S.; Ryeon, D.; Lindsay, J.A.; Friedrich, A.W.; Kearns, A.M.; Westh, H.; Mackenzie, F.M. Methicillin-resistant *Staphylococcus aureus* (MRSA): Global epidemiology and harmonisation of typing methods. *Int. J. Antimicrob. Agents* 2012, 39, 273–282.
45. Song, J.H.; Hsueh, P.R.; Chung, D.R.; Ko, K.S.; Kang, C.I.; Peck, K.R.; Yeom, J.S.; Kim, S.W.; Chang, H.H.; Kim, Y.S.; et al. Spread of methicillin-resistant *Staphylococcus aureus* between the community and the hospitals in Asian countries: An ANSORP study. *J. Antimicrob. Chemother.* 2011, 66, 1061–1069.
46. Hiramatsu, K.; Hanaki, H.; Ino, T.; Yabuta, K.; Oguri, T.; Tenover, F.C. Methicillin-resistant *Staphylococcus aureus* clinical strain with reduced vancomycin susceptibility. *J. Antimicrob. Chemother.* 1997, 40, 135–136.
47. Centers for Disease Control and Prevention. *Staphylococcus aureus* resistant to vancomycin—United States, 2002. *M MWR Morb. Mortal. Wkly. Rep* 2002, 51, 565–567.
48. Howden, B.P.; Davies, J.K.; Johnson, P.D.; Stinear, T.P.; Grayson, M.L. Reduced vancomycin susceptibility in *Staphylococcus aureus*, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: Resistance mechanisms, laboratory detection, and clinical implications. *Clin. Microbiol. Rev.* 2010, 23, 99–139.
49. Bandyopadhyay, D. In response to “Effectiveness of topical green tea against multidrug-resistant *Staphylococcus aureus* in cases of primary pyoderma: An open controlled trial”. *Indian J. Dermatol. Venereol. Leprol.* 2018, 84, 309–310.
50. Akanbi, B.O.; Mbe, J.U. Occurrence of methicillin and vancomycin resistant *Staphylococcus aureus* in University of Abuja Teaching Hospital, Abuja, Nigeria. *Afr. J. Clin. Exp. Microbiol.* 2013, 14, 10–13.
51. Al-Talib, H.I.; Yean, C.Y.; Al-Jashamy, K.; Hasan, H. Methicillin-resistant *Staphylococcus aureus* nosocomial infection trends in Hospital Universiti Sains Malaysia during 2002–2007. *Ann. Saudi Med.* 2010, 30, 358–363.
52. Rigby, K.M.; DeLeo, F.R. Neutrophils in innate host defense against *Staphylococcus aureus* infections. *Semin. Immunopathol.* 2012, 34, 237–259.

53. Weinstein, R.A.; Fridkin, S.K. Vancomycin-intermediate and-resistant *Staphylococcus aureus*: What the infectious disease specialist needs to know. *Clin. Infect. Dis.* 2001, 32, 108–115.
54. Gardete, S.; Tomasz, A. Mechanisms of vancomycin resistance in *Staphylococcus aureus*. *J. Clin. Investig.* 2014, 124, 2836–2840.
55. Kali, A. Antibiotics and bioactive natural products in treatment of methicillin resistant *Staphylococcus aureus*: A brief review. *Pharmacogn. Rev.* 2015, 9, 29–34.
56. McNulty, C.; Rodgers, G.L.; Mortenson, J.E. An overview of the topical antimicrobial agents used in the treatment of burn wounds. *Contin. Educ. Top.* 2004, 74–78.
57. Hemaiswarya, S.; Kruthiventi, A.K.; Doble, M. Synergism between natural products and antibiotics against infectious diseases. *Phytomedicine* 2008, 15, 639–652.
58. Getha, K.; Hatsir, M.; Wong, H.J.; Lee, S.S. Submerged cultivation of basidiomycete fungi associated with root diseases for production of valuable bioactive metabolites. *J. Trop. For. Sci.* 2009, 21, 1–7.
59. Smania, A., Jr.; Monache, F.D.; Loguercio-Leite, C.; Smania, E.d.F.A.; Gerber, A.L. Antimicrobial Activity of Basidiomycetes. *Int. J. Med. Mushrooms* 2001, 3, 2–3.
60. Mothana, R.A.; Jansen, R.; Julich, W.D.; Lindequist, U. Ganomycins A and B, new antimicrobial farnesyl hydroquinones from the basidiomycete *Ganoderma pfeifferi*. *J. Nat. Prod.* 2000, 63, 416–418.
61. Vamanu, E. In vitro antimicrobial and antioxidant activities of ethanolic extract of lyophilized mycelium of *Pleurotus ostreatus* PQMZ91109. *Molecules* 2012, 17, 3653–3671.
62. Finimundy, T.C.; Barros, L.; Calhelha, R.C.; Jose, M.; Prieto, M.A.; Abreu, R.M.V.; Dillon, A.J.P.; Henriques, J.A.P.; Rocha-Ely, M.; Ferreira, C.F.R. Multifunctions of *Pleurotus sajor-caju* (Fr.) Singer: A highly nutritious food and a source for bioactive compounds. *Food Chem.* 2018, 245, 150–158.
63. Mudalungu, C.M.; Richter, C.; Wittstein, K.; Abdalla, M.A.; Matasyoh, J.C.; Stadler, M.; Suessmuth, R.D. Laxitextines A and B, cyathane xylosides from the tropical fungus *Laxitextum incrustatum*. *J. Nat. Prod.* 2016, 79, 894–898.
64. Tareq, F.S.; Hasan, C.M.; Rahman, M.M.; Hanafi, M.M.M.; Colombi Ciacchi, L.; Michaelis, M.; Spiteller, P. Anti-*Staphylococcal* Calopins from Fruiting Bodies of *Caloboletus radicans*. *J. Nat. Prod.* 2018, 81, 400–404.
65. Ma, K.; Bao, L.; Han, J.; Jin, T.; Yang, X.; Zhao, F.; Li, S.; Song, F.; Liu, M.; Liu, H. New benzoate derivatives and hirsutane type sesquiterpenoids with antimicrobial activity and cytotoxicity from the solid-state fermented rice by the medicinal mushroom *Stereum hirsutum*. *Food Chem.* 2014, 143, 239–245.
66. Bitew, A. Antibacterial and antifungal activities of culture filtrate extract of *Pyroformes demidoffii* (Basidiomycete). *World Appl. Sci. J.* 2010, 10, 861–866.
67. Waitthaka, P.N.; Gathuru, E.M.; Githaiga, B.M.; Onkoba, K.M. Antimicrobial activity of mushroom (*Agaricus bisporus*) and fungal (*Trametes gibbosa*) extracts from mushrooms and fungi of Egerton main campus, Njoro Kenya. *J. Biomed. Sci.* 2017, 6, 1–6.
68. Reid, T.; Kashangura, C.; Chidewe, C.; Benhura, M.A.; Mduluzi, T. Antibacterial properties of wild edible and non-edible mushrooms found in Zimbabwe. *Afr. J. Microbiol. Res.* 2016, 10, 977–984.
69. Gebreyohannes, G.; Nyerere, A.; Bii, C.; Sbhata, D.B. Determination of antimicrobial activity of extracts of indigenous wild mushrooms against pathogenic organisms. *Evid. Based Complement. Altern. Med.* 2019, 2019.
70. Muhsin, T.M.; Mohammad, H.M. Antibacterial Bioactive Compound from The Fungus *Drechslera Halodes* (Drechsler) Subram. Jain Isolated from Soil of Basrah, Iraq. *Sci. J. Univ. Zakho* 2013, 1, 508–514.